The estimated Net Worth of Robert Hoffman is at least $959 Thousand dollars as of 2 July 2018. Mr. Hoffman owns over 30,000 units of Kura Oncology Inc stock worth over $621,846 and over the last 21 years he sold KURA stock worth over $110,000. In addition, he makes $227,570 as Independent Director at Kura Oncology Inc.
Sign up
Mr. Hoffman KURA stock SEC Form 4 insiders trading
Robert has made over 7 trades of the Kura Oncology Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 30,000 units of KURA stock worth $459,000 on 2 July 2018.
The largest trade he's ever made was exercising 71,250 units of Kura Oncology Inc stock on 1 April 2013 worth over $128,963. On average, Robert trades about 3,142 units every 40 days since 2003. As of 2 July 2018 he still owns at least 31,280 units of Kura Oncology Inc stock.
You can see the complete history of Mr. Hoffman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Hoffman biography
Robert E. Hoffman serves as Independent Director of the Company. Mr. Hoffman has served as Chief Financial Officer and Senior Vice President of Heron Therapeutics, Inc., a publicly-held biotechnology company, since April 2017. Prior to joining Heron Therapeutics, Inc., Mr. Hoffman served as Executive Vice President and Chief Financial Officer of Innovus Pharmaceuticals, Inc., a publicly-held pharmaceutical company, from September 2016 to April 2017. Mr. Hoffman served as Chief Financial Officer of AnaptysBio, Inc., a publicly-held biotechnology company, from July 2015 to September 2016. Mr. Hoffman was the Senior Vice President, Finance and Chief Financial Officer of Arena Pharmaceuticals, Inc. (“Arena”), a publicly-held biopharmaceutical company, from June 2012 to July 2015, Vice President, Finance and Chief Financial Officer of Arena from August 2011 to June 2012 and previously from December 2005 to March 2011 and in a number of roles of increasing responsibility from 1997 to December 2005. From March 2011 to August 2011, Mr. Hoffman served as Chief Financial Officer for Polaris Group, a biopharmaceutical drug company. Mr. Hoffman serves as a member of the Financial Accounting Standards Board’s Small Business Advisory Committee and the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman is also a member and a former director and President of the San Diego Chapter of Financial Executives International. Mr. Hoffman has been a member of the Board of Directors of DelMar Pharmaceuticals, Inc., a publicly-held biotechnology company, since April 2018, and ASLAN Pharmaceuticals, Inc, a publicly-held biotechnology company, since October 2018. Previously, Mr. Hoffman was a member of the Board of Directors of CombiMatrix Corporation, a publicly-held molecular diagnostics company, from 2013 to 2017, MabVax Therapeutics Holdings, Inc., a publicly-held biopharmaceutical company, from 2014 to 2017, and Aravive, Inc., a publicly-held biotechnology company, from October 2018 to April 2020.
What is the salary of Robert Hoffman?
As the Independent Director of Kura Oncology Inc, the total compensation of Robert Hoffman at Kura Oncology Inc is $227,570. There are 12 executives at Kura Oncology Inc getting paid more, with Kathleen Ford having the highest compensation of $3,485,030.
How old is Robert Hoffman?
Robert Hoffman is 54, he's been the Independent Director of Kura Oncology Inc since 2015. There are 6 older and 13 younger executives at Kura Oncology Inc. The oldest executive at Kura Oncology Inc is Kathleen Ford, 74, who is the Chief Operating Officer.
What's Robert Hoffman's mailing address?
Robert's mailing address filed with the SEC is C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA, 92130.
Insiders trading at Kura Oncology Inc
Over the last 6 years, insiders at Kura Oncology Inc have traded over $16,903,587 worth of Kura Oncology Inc stock and bought 50,000 units worth $575,000 . The most active insiders traders include Faheem Hasnain, Troy Edward Wilson, and Mary T Szela. On average, Kura Oncology Inc executives and independent directors trade stock every 63 days with the average trade being worth of $626,260. The most recent stock trade was executed by Teresa Brophy Bair on 20 May 2024, trading 2,615 units of KURA stock currently worth $57,922.
What does Kura Oncology Inc do?
at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.
What does Kura Oncology Inc's logo look like?
Complete history of Mr. Hoffman stock trades at Arena Pharmaceuticals Inc, DelMar Pharmaceuticals, Heron Therapeutics Inc, Kura Oncology Inc, and Aravive Inc
Kura Oncology Inc executives and stock owners
Kura Oncology Inc executives and other stock owners filed with the SEC include:
-
Kathleen Ford,
Chief Operating Officer -
Troy Wilson,
Chairman of the Board, President, Chief Executive Officer -
Marc Grasso,
Chief Financial Officer and Chief Business Officer -
James Basta,
Chief Legal Officer and Secretary -
Dr. Troy Edward Wilson,
Chairman, CEO & Pres -
Dr. Troy Edward Wilson J.D., Ph.D.,
Chairman, CEO, Pres & Principal Financial Officer -
Dr. Marc Grasso,
CFO & Chief Bus. Officer -
Kathleen Ford,
Chief Operating Officer -
Kirsten Flowers,
Chief Commercial Officer -
Dr. Marc Grasso M.D.,
Advisor -
Dr. Stephen Dale M.D.,
Chief Medical Officer -
Diane Parks,
Independent Director -
Robert Hoffman,
Independent Director -
Faheem Hasnain,
Lead Independent Director -
Thomas Malley,
Independent Director -
Steven Stein,
Independent Director -
Mary Szela,
Independent Director -
Bridget Martell,
Acting Chief Medical Officer -
Kirsten Flowers,
Chief Commercial Officer -
Stephen Dale,
Chief Medical Officer -
Thomas Doyle,
Principal Accounting Officer & Sr. VP of Fin. and Accounting -
Dr. Nic G. Scalfarotto,
Sr. VP of Regulatory Affairs -
Dr. Roger Bakale Ph.D.,
VP and Head of CMC, Clinical & Commercial Manufacturing -
Teresa Brophy Bair Esq., J.D.,
Chief Legal Officer & Corp. Sec. -
James E. Basta J.D., Esq.,
Chief Compliance Officer & Corp. Sec. -
Pete De Spain,
VP of Investor Relations & Corp. Communications -
Teresa Brophy Bair,
Chief Legal Officer -
Antonio Gualberto,
Head of Development & CMO -
Pingda Ren,
SVP Chemistry&Pharma Sciences -
Annette North,
SVP, General Counsel -
Carol Schafer,
-
Helen Louise Collins,
-
Brian T. Powl,
Chief Commercial Officer -
Thomas James Doyle,
SVP, Finance & Accounting